drugset / Trial / NCT03634059
A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of apatinib plus EGFR-TKI as first line treatment in patients with non-squamous NSCLC harboring EGFR mutation.
Timeline
- Start
- 2018-08-15
- Primary completion
- 2019-08-15
- Completion
- 2020-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Icotinib | Small molecule | 125 mg | Oral |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |